Please assess the completion status of the following clinical trial:

Trial Title: Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Creatinine clearance ≤40 mL/min~* Hemoglobin 110-120 g/L~* Serum ferritin \<100 µg/L or transferrin saturation \<20%~* Monthly treatment with ESA and oral iron for at least six months before enrolment~Exclusion Criteria:~* Other obvious cause of acute or chronic anemia than iron deficiency~* Expectation to require hemodialysis within the next six months~* Short life expectancy (\<1 year)~* Pregnancy~* Decompensated heart failure~* History of allergic reactions to iron preparations and/or anaphylaxis from any cause~* Requirement of blood transfusions~* Chronic decompensated mental disorder or dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intravenous ferric carboxymaltose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).